Temasek Holdings’s Vir Biotechnology VIR Stock Holding History

Temasek Holdings’s Portfolio VIR Stock Details VIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-5,133,610	Closed	-$126M	–	91
2023 Q2	$126M	Sell	5,133,610 -681,362	-12%	-$17.1M	0.73%	31
2023 Q1	$135M	Buy	5,814,972 +104,462	+2%	+$2.67M	0.8%	29
2022 Q4	$145M	Sell	5,710,510 -326,311	-5%	-$8M	0.84%	32
2022 Q3	$116M	Buy	6,036,821 +434,268	+8%	+$11M	0.7%	35
2022 Q2	$143M	Hold	5,602,553	–	–	0.78%	31
2022 Q1	$144M	Buy	5,602,553 +65,262	+1%	+$1.94M	0.61%	33
2021 Q4	$232M	Sell	5,537,291 -223,754	-4%	-$8.77M	0.84%	30
2021 Q3	$251M	Buy	5,761,045 +149,170	+3%	+$6.46M	0.88%	26
2021 Q2	$265M	Buy	5,611,875 +93,231	+2%	+$4.24M	0.89%	25
2021 Q1	$283M	Buy	5,518,644 +18,645	+0.3%	+$1M	1.11%	20
2020 Q4	$147M	Hold	5,499,999	–	–	0.63%	28
2020 Q3	$189M	Hold	5,499,999	–	–	0.96%	19
2020 Q2	$225M	Hold	5,499,999	–	–	1.35%	15
2020 Q1	$188M	Hold	5,499,999	–	–	1.39%	16
2019 Q4	$69.2M	Buy	+5,499,999	New	+$73.7M	0.45%	30

Other funds holding VIR

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Temasek Holdings's VIR Position: Q3 2023 in Review

Temasek Holdings sold out of Vir Biotechnology (VIR) in Q3 2023, closing a stake of 5,133,610 shares — an estimated $126M sold.

Temasek Holdings first reported a position in VIR in Q4 2019 and held it in 15 quarters. The position peaked at $283M in Q1 2021. 214 funds tracked by Wall St. Rank hold VIR as of Q3 2023.

Temasek Holdings reported no remaining Vir Biotechnology position as of Q3 2023 after selling out during the quarter.
Temasek Holdings sold 5,133,610 Vir Biotechnology shares in Q3 2023, an estimated $126M.
Temasek Holdings first reported a position in Vir Biotechnology in Q4 2019 and held it in 15 quarters.
Temasek Holdings's Vir Biotechnology position peaked at $283M in Q1 2021.
214 funds tracked by Wall St. Rank held Vir Biotechnology as of Q3 2023.

Based on Temasek Holdings's 13F filing for Q3 2023, filed 14 Nov 2023.